Investor Relations

MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology that address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe. NexoBrid  represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissues.

  • Intra
  • 3 mo.
  • 6 mo.
  • 1 yr.

Press Releases

  • September 3, 2021
    YAVNE, Israel , Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management will present at the following
  • August 10, 2021
    Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year Positive Interim Assessment Outcome for EscharEx U.S. Phase II Clinical Study No Changes to Study Sample Size – No Safety Concerns Identified Conference call begins today at 8:30 am ET   YAVNE, Israel , Aug.

Events & Presentations

Investor Presentation

mediwound image